CELON PHARMA S.A. ZY-10
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.
CELON PHARMA S.A. ZY-10 (8RP) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CELON PHARMA S.A. ZY-10 (8RP) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CELON PHARMA S.A. ZY-10 - Net Assets Trend (None–None)
This chart illustrates how CELON PHARMA S.A. ZY-10's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CELON PHARMA S.A. ZY-10 (None–None)
The table below shows the annual net assets of CELON PHARMA S.A. ZY-10 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CELON PHARMA S.A. ZY-10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CELON PHARMA S.A. ZY-10 Competitors by Market Cap
The table below lists competitors of CELON PHARMA S.A. ZY-10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
lastminute.com N.V
PINK:LSMNF
|
$126.49 Million |
|
Mokingran Jewellery Group Co., Ltd.
F:0HY
|
$126.52 Million |
|
Clasquin
PA:ALCLA
|
$126.60 Million |
|
Zeda Ltd.
JSE:ZZD
|
$126.62 Million |
|
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd
SHG:600671
|
$126.36 Million |
|
United Pharm
KO:033270
|
$126.28 Million |
|
Journey Medical Corp
NASDAQ:DERM
|
$126.26 Million |
|
Cool Company Oy
OL:CLCO
|
$126.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CELON PHARMA S.A. ZY-10's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CELON PHARMA S.A. ZY-10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CELON PHARMA S.A. ZY-10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CELON PHARMA S.A. ZY-10's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CELON PHARMA S.A. ZY-10 (8RP) | €- | N/A | N/A | $126.43 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $249.40K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.45K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $936.86 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $60.78 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $35.80 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.87 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |